Surrogate endpoint

Results: 164



#Item
131Acute myeloid leukemia / Minimal residual disease / CD135 / Acute leukemia / Myeloid leukemia / Leukemia

Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Leukemia-associated Immunophenotypes for MRD detection in AML Adriano Venditti

Add to Reading List

Source URL: www.fda.gov

Language: English
132Lymphocytic leukemia / Acute leukemia / Clinical trials / Medical research / Medical terms / Surrogate endpoint / Biomarker / B-cell chronic lymphocytic leukemia / Minimal residual disease / Medicine / Oncology / Health

Federal Register / Vol. 77, No[removed]Wednesday, December 26, [removed]Notices The public workshop will be held on March 4, 2013, from 8 a.m. to 4 p.m. ADDRESSES: The public workshop will be held at the FDA White Oak Campu

Add to Reading List

Source URL: www.gpo.gov

Language: English - Date: 2012-12-22 11:14:57
133Cancer organizations / Clara D. Bloomfield / Hematologists / Food and Drug Administration / Center for Drug Evaluation and Research / Acute myeloid leukemia / Fred Hutchinson Cancer Research Center / Timothy Ley / Brian Monahan / Medicine / Oncology / Oncologists

Minimal Residual Disease (MRD) as a Surrogate Endpoint in Acute Myeloid Leukemia (AML) Workshop Meeting Roster

Add to Reading List

Source URL: www.fda.gov

Language: English
134Clinical research / Center for Devices and Radiological Health / Center for Drug Evaluation and Research / Biologic / Center for Biologics Evaluation and Research / Surrogate endpoint / FDA Fast Track Development Program / Clinical trial / Federal Food /  Drug /  and Cosmetic Act / Food and Drug Administration / Medicine / Health

Regulatory Basis for U.S. Drug & Biologics Approval Paul G. Kluetz, M.D. Office of Hematology and Oncology Products

Add to Reading List

Source URL: www.fda.gov

Language: English
135Lymphocytic leukemia / Minimal residual disease / Clinical trials / Medical research / Medical terms / Surrogate endpoint / Food and Drug Administration / Leukemia / Center for Drug Evaluation and Research / Medicine / Health / B-cell chronic lymphocytic leukemia

MINIMAL RESIDUAL DISEASE (MRD) WORKSHOP

Add to Reading List

Source URL: www.fda.gov

Language: English
136Leukemia / Minimal residual disease / Acute myeloid leukemia / Surrogate endpoint / Medicine / Acute leukemia / Myeloid leukemia

MINIMAL RESIDUAL DISEASE (MRD) WORKSHOP

Add to Reading List

Source URL: www.fda.gov

Language: English
137Medicine / Medical statistics / Food and Drug Administration / Clinical Data Management / Patient-reported outcome / Clinical trial / Surrogate endpoint / Clinical research / Research / Epidemiology

COA_DDT_charts_131004_Roadmap

Add to Reading List

Source URL: www.fda.gov

Language: English
138Medical research / Biotechnology / Emerging technologies / Food and Drug Administration / Pharmacology / United States Public Health Service / Gene therapy / Center for Biologics Evaluation and Research / Surrogate endpoint / Medicine / Biology / Health

HHS Letterhead ONLY Template

Add to Reading List

Source URL: www.fda.gov

Language: English
139Research / Clinical research / Medical statistics / Clinical trials / Medical terms / Surrogate endpoint / Clinical endpoint / Biomarker / Randomized controlled trial / Medicine / Epidemiology / Health

Session 1: Complex Issues for Trial Design: Endpoints Public Workshop on the Complex Issues in Developing Drug and Biological Products for Rare Diseases January 6 & 7, 2014

Add to Reading List

Source URL: www.fda.gov

Language: English
140Biology / Antiretroviral drug / Surrogate endpoint / AIDS Clinical Trials Group / Zidovudine / HIV / Neopterin / Viral load / AIDS / HIV/AIDS / Medicine / Health

1998 CONFERENCE ON THE LABORATORY SCIENCE OF HIV AN APPROACH TO THE VALIDATION OF MARKERS FOR USE IN AIDS CLINICAL TRIALS Donna Mildvan, M.D., et al.* Chief, Division of Infectious Diseases

Add to Reading List

Source URL: wwwn.cdc.gov

Language: English - Date: 2006-11-06 14:31:28
UPDATE